RMTC Suspends Accreditation of UK Laboratory

The Racing Medication and Testing Consortium (RMTC) has suspended its accreditation of the University of Kentucky's Equine Analytical Chemistry Laboratory, according to the RMTC's executive director, Michael Hardy.

This follows news last week that the Horseracing Integrity and Safety Authority (HISA) and Horseracing Integrity and Welfare Unit (HIWU) have opened an investigation into the UK Laboratory's performance, and that the agencies were cooperating with the university's own investigation into the matter.

The university is also conducting an ongoing personnel investigation relating to former lab director Scott Stanley and that “Dr. Stanley was not permitted to be in direct communication with the other staff at the laboratory,” HISA and HIWU wrote in a joint statement last week.

According to Stanley, he stepped down as the UK Lab's director at the beginning of March and has been reassigned within the university. Blood-Horse reported that he had been “removed” from the position.

HIWU stopped sending samples to the UK Lab on Feb. 16. Prior to that, the laboratory had been one of six drug testing facilities used under HISA's Anti-Doping and Medication Control (ADMC) program. According to the RMTC's Hardy, his organization alerted the University of Kentucky to the RMTC's laboratory accreditation suspension on Mar. 11.

When asked what specific developments had prompted the RMTC to take this action, Hardy pointed to the RMTC's laboratory code of standards, section 2.4.9.2.

The document outlines 10 possible considerations that may prompt the RMTC to suspend its accreditation of a laboratory:

  • Accreditation suspensions by international lab oversight bodies.
  • Failure to take appropriate corrective action after unsatisfactory performance either in routine Analytical Testing or in proficiency testing.
  • Failure to comply with any of the requirements or standards listed in an international laboratory accreditation cooperation document.
  • Failure to cooperate with the RMTC or the relevant State Horse Racing Authority in providing requested documentation.
  • Lack of compliance with the RMTC Laboratory Code of Ethics.
  • Major changes in key staff without proper and timely notification to RMTC.
  • Failure to cooperate in any RMTC enquiry in relation to the activities of the Laboratory.
  • Non-compliances identified from laboratory on-site assessments.
  • Loss of financial and administrative support jeopardizing the quality and/or viability of the Laboratory.
  • Material breach of contractual obligation to a State Horse Racing Authority.

Hardy declined to elaborate on the nature and severity of the issues identified by the RMTC with operations at the UK Lab. Hardy wrote, however, that “the Horserace Testing Laboratory Committee (HTLC) will, upon receipt, review the laboratory's response and associated corrective actions. Accreditation will not be restored until the laboratory is in full compliance with the Code.”

According to the RMTC's code of standards, the “period and terms” of the suspension shall be proportionate to the “seriousness of the non-compliance(s) or lack of performance and the need to ensure accurate and reliable drug testing of Horses.”

The RMTC can suspend accreditation for a period of up to six months, according to the code of standards, during which time any problems must be “corrected, documented and reported” to the RMTC at least six weeks before the end of the suspension period.

“Delay in submitting the proper corrective actions may lead to an extension of the Suspension period,” the code of standards explains. If the problems are not rectified, laboratory accreditation will be revoked, the document states, “unless an extension, not to exceed two (2) months, is granted by the RMTC.”

In a brief phone interview with the TDN, Hardy added that the RMTC has been “very pleased with the response and communication with executive staff at the University of Kentucky regarding the laboratory and have been assured that they are proactively seeking to redeem those requirements.”

Since Feb. 16, all samples collected in Kentucky and Florida that previously would have been analyzed by the UK Lab have been redirected to Industrial Laboratories in Colorado.

The TDN has reached out to the University of Kentucky for comment. The story will be updated as necessary.

According to a HIWU spokesperson, both agencies were “not party” to the RMTC's decision to suspend its accreditation of the UK Lab.

“Pending implementation of the HISA Equine Analytical Laboratory (HEAL) accreditation standards, a laboratory must be accredited by the RMTC to be eligible for consideration as one of the ADMC Program labs,” the HIWU spokesperson wrote.

Lab accreditation is only one prong of the RMTC, which is also involved in the research, education and advocacy of horse racing's anti-doping and medication control programs.

The post RMTC Suspends Accreditation of UK Laboratory appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

HIWU: Efforts to Harmonize Laboratory “Testing Sensitivity” Underway

In a statement Thursday, the Horseracing Integrity and Welfare Unit (HIWU)–the enforcement arm of the Horseracing Integrity and Safety Act (HISA)–said that an internal review of the six accredited laboratories used by the agency had unearthed different limits of detection in blood for metformin, a banned substance at all times under HISA.

“Following this review, which was conducted in collaboration with the laboratories, it was determined that not all applied the same Limit of Detection in analyzing samples for the presence of Metformin. HIWU has since met with all six laboratories to establish an updated, uniform Limit of Detection,” according to the HIWU statement.

Furthermore, “there are efforts to harmonize testing sensitivity across the laboratories through an external quality assurance program that includes single- and double-blind quality assurance samples and a passed sample exchange program,” according to the HIWU statement.

“Additionally, substances will continue to be reviewed on a case-by-case basis to ensure that all laboratories contracted by HIWU report uniform results for the same substances present at the same levels in different samples,” the statement reads.

All HIWU-contracted laboratories contracted are accredited by the Racing Medication & Testing Consortium.

According to HIWU, HISA's Equine Analytical Laboratory Accreditation standards are currently in development, and HIWU expects the process to continue through 2024.

Because of this flaw in testing uniformity, HIWU has lifted the provisional suspensions it had initially imposed on trainers Guadalupe Munoz Elizondo and Javier Morzan for metformin positives.

The agency wrote that it will also be withdrawing the Equine Anti-Doping Charge letters against Elizondo and Morzan “due to their Covered Horses testing positive for Metformin at levels in blood that would not have been reported as Adverse Analytical Findings under the updated Limit of Detection.”

Elizondo trainee, Quinton's Charmer (Quinton's Gold), tested positive for metformin, a common type 2 diabetes drug in humans, in a sample taken June 11 this year.

The Morzan-trained Lady Liv (Bal A Bali) tested positive for metformin after finishing third at Delaware Park June 24.

Elizondo and Morzan were two of five trainers this past week who have seen their provisional suspensions lifted by HIWU. Besides the metformin cases, two were for cocaine positives, and one was for the diuretic hydrochlorothiazide.

On Tuesday, Michelle Pujals, HIWU general counsel, sent Elizondo a letter explaining the decision behind lifting the provisional suspension.

In the letter, Pujals wrote that “HIWU has determined that there was variability across laboratories with respect to Limit of Detection for this Banned Substance, and, in order to eliminate inconsistency in enforcement based on interlaboratory capabilities, HIWU is determining whether this finding will be pursued as an Adverse Analytical Finding.”

On Wednesday, TDN submitted to HIWU a list of questions about the contents of the letter, including further explanations on what was meant by “variability across laboratories,” and “inconsistency in enforcement based on interlaboratory capabilities.”

TDN will follow-up with HIWU about the remaining questions unanswered by Thursday's statement.

There remain three trainers with pending hearings for metformin positives whose provisional suspensions have not been lifted by HIWU. They are Jonathan Wong, Angel Sanchez and Michael Lauer.

In Thursday's statement, HIWU wrote that the review of and update to the metformin limit of detection in blood represents “progress from previous state-based regulatory structures in which laboratories historically operated independently of each other, resulting in substances being controlled differently depending on the laboratory conducting the testing.”

The statement adds that “HISA's national structure enables HIWU to oversee all testing across the country and facilitate uniform enforcement of the ADMC rules. HIWU is committed to the harmonization of its laboratories and continues to work with them to reach this goal.”

The post HIWU: Efforts to Harmonize Laboratory “Testing Sensitivity” Underway appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

RMTC Promotes Hardy to Full-Time Executive Director

The Racing Medication & Testing Consortium (RMTC)'s part-time Executive Director, Dr. Michael Hardy, has been promoted to full-time Executive Director of the RMTC, the organization announced on Monday.

In his new position, Hardy will be responsible for the management of the RMTC's Laboratory Accreditation and External Quality Assurance Program in conjunction with the new Horseracing Integrity and Welfare Unit and will also administer the RMTC's Scientific Advisory Committee (SAC) process, manage the organization's monitoring of emerging threats to the integrity of racing, and oversee the process of reviewing applications received for all RMTC-funded post-doctoral fellowships and research proposals.

“We are very pleased to have Dr. Hardy on board in a full-time capacity,” RMTC Chair Alex Waldrop said. “The Board of Directors has determined that the work of the RMTC and its scientific advisory committee continue to be uniquely relevant to the horseracing industry's efforts to fairly and safely regulate the use of therapeutic medications and aggressively detect and deter the use of prohibited substances. In this regard, Dr. Hardy is the right person to lead these important efforts going forward.”

Also during its recent meeting, the RMTC Board approved the development, organization, and financial support of a Racing Industry Veterinary Student Externship Program in response to the supply and demand concerns associated with available equine-specific veterinarians to meet the racing industry needs. This program will provide a shared experience for veterinary students with racetrack practitioners and regulatory veterinarians with the objective to promote and provide exposure to and networking opportunities in equine veterinary medicine within the racing industry to prospective veterinarians.

“The success of the racing industry is dependent on the recruitment, availability, and retention of motivated attending and regulatory veterinary professionals to oversee the safety and welfare of its participants,” Hardy said. “The RMTC will join other equine industry organizations taking an active role in promoting careers in equine veterinary medicine.”

The post RMTC Promotes Hardy to Full-Time Executive Director appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

HIWU’s Scollay: New Medication Rules ‘Your New Bible’

Despite all the legal jockeying these past few weeks and months, the Horseracing Integrity and Safety Act's (HISA) anti-doping and medication control program still appears set for launch on Jan. 1 in the vast majority of states that conduct pari-mutuel wagering.

This means on the first day of 2023, thousands of trainers, veterinarians and other backstretch workers must grapple with a new set of rules guiding how and when to administer a set of everyday medications–the list of which can be found here–to avoid falling foul of a post-race and out-of-competition positive.

Is there much of a difference between the Association of Racing Commissioners International (ACRI)'s current therapeutic medication schedule and that as outlined by the Horseracing Integrity and Welfare Unit (HIWU)?

Turns out there is–one that, in short, boils down to the differences between the current world of withdrawal guidelines and thresholds, and the looming system of detection times and screening limits.

“There is a substantial difference and if the terms are used interchangeably, there is a profound risk of a medication violation,” warned Mary Scollay, chief of science at HIWU, established by Drug Free Sport International.

Some of the key points as Jan. 1 looms large:

 

  • Detection times do not necessarily provide an accurate medication withdrawal guide;

 

  • New screening limits will require different administration protocols;

 

  • There will be no enforcement “grace period” for stakeholders to adjust.

 

  • This different medication schedule will require adjustments well before Jan. 1;

 

Withdrawal Guidelines vs. Detection Times

Traditionally, withdrawal guidelines are based on administration studies with a “statistically derived margin of safety built in,” said Scollay.

“The idea is that if you follow the administration protocol described in the study–dose, route of administration–and you comply with the withdrawal guidance,” said Scollay, “you should have a high degree of confidence that you will not have a medication violation.”

In other words, withdrawal guidelines provide a reliable cut-off point to administer a medication to avoid post-race positives.

This is in contrast to detection times under HISA, calculated through studies on a group of horses administered a certain medication.

These horses are then tested to determine the earliest time the drug is eliminated from all the horses' systems–a level below either the lowest concentration identified by the laboratory or below a defined screening limit.

This means that detection times “do not have any margin of safety calculated in,” warned Scollay. “It is the starting point for determining a withdrawal interval. So, the burden for establishing an appropriate withdrawal interval for medication now lies exclusively with the horses' connections.”

In any of these given studies, for example, the horses may metabolize drugs at different speeds–and potentially quicker than a racehorse given the same drug at the same dose.

Studies with a very small cohort of horses–like hydroxyzine, with a detection time of 96 hours from a study with only two horses–provide another reason why detection times can provide a very thin margin of error.

Imagine a study testing a doorframe set at six feet, explained one regulatory veterinarian. If the study participants are all under six foot, no problem. But what about all the six-foot plus individuals not studied?

For practicing veterinarians accustomed to concrete withdrawal times, therefore, this constitutes a sea-change in the way medications can be safely prescribed and administered to avoid costly post-race positives.

“There's no easy answer to this,” admitted Scollay. “I fully understand what a philosophical change this is, and yes, I understand that the vets can feel like they're flying blind right now.”

Aim of Schedule

Aside from a select few substances–like electrolytes, orally administered vitamins and anti-ulcer medications which can be administered up to 24-hours before a race–there is a mandatory 48-hour restricted administration time for all controlled medications.

For a number of these routine controlled medications, the dosage, withdrawal time and stipulated threshold in the current ARCI schedule are the same as the dosage, detection time and screening limits outlined by HIWU.

But where these differ, the differences might be subtle, easily over-looked. The ARCI's phenylbutazone threshold is 0.3 micrograms per millimeter, but is 0.2 micrograms per millimeter under HISA, for example–a small change with significant implications when it comes to its use in the days prior to a race. What's more, Scollay is unable to provide veterinarians and horsemen with specific withdrawal numbers. “HIWU and HISA are not in a position to provide withdrawal guidance,” she said. “I cannot say, 'I think you're going to be fine if you back out to 82 hours.'”

Things can get even trickier when HIWU provides zero dosage, detection time and screening limit guidance on a drug listed on the controlled medication list. But that doesn't necessarily mean veterinarians and trainers are indeed “flying blind.”

The corticosteroid betamethasone has no dosage or detection time listed, but it comes with a Restricted Administration Time (RAT) to race of 14 days (7 days for a work).

The Non-steroidal anti-inflammatory drug (NSAID) diclofenac–commonly found in a topical ointment to treat swelling and inflammation–similarly has no listed dosage and detection time.

As Scollay explains, that's because the process of calculating elimination times in an ointment–and therefore, one routinely applied in wildly different amounts to different parts of the body–is extremely difficult.

But this underscores, she said, the overarching aim of the new medication schedule–to foster a more conservative approach to veterinary medicine.

If diclofenac is used to treat a problematic joint, said Scollay, “from my perspective, once you've got that joint quieted down, I think you'd still want to assess that horse's response to treatment and assess the horse's recovery by breezing him.

“And so, you're not talking about ceasing treatment on a specific joint that has been inflamed and problematic going into a race in three days.”

In other words, if a topical diclofenac ointment is being used to treat certain musculoskeletal problems, then racing probably shouldn't be on the horse's imminent agenda, said Scollay.

Clearance Testing

More broadly, there's a very rough rule-of-thumb when it comes to calculating withdrawal times. One is that a short detection time is typically indicative of fast elimination from the system, said Scollay.

“But if something takes 96 hours to clear, I would be more conservative because I know it clears slowly,” said Scollay, speculating that “if I add just 24 hours onto that, I may not have allowed enough time for it to clear.”

But perhaps the most accurate guide for veterinarians and trainers concerned about a positive test, said Scollay, would be to conduct “clearance testing” well before race-day–a service provided through HIWU.

“We'll collect the sample from the horse, and then send it to the laboratory that's doing the testing. The trainer would have to provide information about the treatment, the drug, the dose, the frequency–when it was halted,” said Scollay.

It's not a free service, however.

“I don't know what that fee is yet,” Scollay added. “That would be paid for by the horse's connections.”

Importantly, the new controlled medication rules are primarily germane to post-race testing, not HISA's out-of-competition testing program, which is largely focused on banned substances.

That said, the new rules prohibit the presence of more than one NSAID or corticosteroid in both post-race and post-work samples–a prohibition designed to nix the practice of “stacking.”

HIWU's new common controlled medication list provides secondary detection times for three common NSAIDS, to help avoid a stacking offense.

Enforcement

Though the new drug rules might prove a marked change from the current status-quo, don't expect an enforcement grace period for stakeholders to acclimatize to their new regulatory expectations.

“The regulations don't provide for it,” said Scollay, categorically.

So, what are some of the implications for a positive of a controlled substance? An outline of the sanctions can be found here.

The majority of post-race positives are for everyday therapeutic medications–like phenylbutazone, a class C controlled drug, a first time positive for which would result in a fine of up to $500 and the automatic disqualification of the horse.

Which leads to another question: Who will be held responsible in the event of a positive?

The ultimate-insurer rule places the burden of responsibility on the shoulders of the trainer. But in the language of the law, there appears to be room for the veterinarian (and perhaps others) to be similarly held culpable.

As Scollay describes it, such a scenario would be case-specific. “The facts of the case would have to determine who else might be complicit,” she said. “To be fair, if it's an overage of a medication one would say, 'well, the vet didn't administer that without the trainer's knowledge and consent.'”

And so, when should veterinarians, trainers and others start applying these new controlled medication rules?

Given the 14-day stand down on all intra-articular injections–along with a 15-day detection time for the NSAID firocoxib–Scollay recommends familiarization with, and application of, the new rules as soon as possible, to avoid regulatory consequences come Jan. 1.

In other words, if trainers and veterinarians are deciding on withdrawal decisions after a horse is entered to race after Jan. 1, “they've waited too long,” said Scollay.

“I think more important is for veterinarians and trainers to review the document together and develop a shared approach to interpreting detection times,” she said. “And there is no time like the present for that.”

Education

Between now and Jan. 1, HIWU will apparently be releasing educational materials aimed towards regulatory and practicing veterinarians, and the trainers themselves.

Another intended event, said Scollay, is a webinar with a noted European veterinarian to explain how detection times and screening limits translate in Europe, where they've been in effect for much longer. Scollay was unable to provide details about then that might be, however.

The Racing Medication and Testing Consortium (RMTC) can act as an information intermediary, said Scollay, who added that industry stakeholders can contact her directly with any drug-related questions.

She also recommends printing off HIWU's controlled medication list—once again linked to here–before laminating and pinning it to the barn wall.

“I've been using the 'L' word every chance I can get. Laminate it, put it on your clipboard. Give them to your staff. That's your new bible,” Scollay said.

“There's no easy answer to this other than be more conservative and be more cautious of medication than you have been,” she said. “And ask yourself, 'does this horse really need it?'”

The post HIWU’s Scollay: New Medication Rules ‘Your New Bible’ appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Verified by MonsterInsights